Skip to main content

Peer Review reports

From: Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial

Original Submission
12 May 2017 Submitted Original manuscript
14 Aug 2017 Reviewed Reviewer Report - S Kümmel
8 Sep 2017 Author responded Author comments - Wei Wu
Resubmission - Version 2
8 Sep 2017 Submitted Manuscript version 2
19 Sep 2017 Reviewed Reviewer Report - S Kümmel
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
5 Oct 2017 Editorially accepted
25 Oct 2017 Article published 10.1186/s13063-017-2228-5

You can find further information about peer review here.

Back to article page